Ziihera Shows Improved Overall Survival in Updated Phase 3 Data
JAZZ sits 97% above its 52-week low of $123.88.
Summary
Jazz announced second interim overall survival results from the Phase 3 HERIZON-GEA-01 trial showing Ziihera plus chemotherapy significantly improved OS versus trastuzumab plus chemotherapy in first-line HER2+ advanced GEA. The OS hazard ratio improved compared with the first interim analysis, and the Ziihera plus tislelizumab and chemotherapy arm also showed improved OS. This follows the FDA approval of Ziihera on August 25 for first-line HER2+ GEA. The updated data reinforce Ziihera as a new standard of care and will be presented at a major medical meeting in Q4 2026, with submissions to global health authorities planned.
At the time of this announcement, JAZZ was trading at $244.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $123.88 to $266.38. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.